X0306 4 2021-02-27 0000078003 PFIZER INC PFE 0001678459 MACKENZIE ALEXANDER R PFIZER INC.-CORP. SECRETARY 235 EAST 42ND ST. NEW YORK NY 10017 1 Executive Vice President Common Stock 2021-02-27 4 M 0 29838.0000 22.3500 A 153338.0000 D Common Stock 2021-02-27 4 F 0 5812.0000 33.4900 D 147526.0000 D Common Stock 2021-02-27 4 F 0 18919.0000 34.6400 D 128607.0000 D Common Stock 10111.0000 I By Rule 16b-3 Plan Stock Appreciation Rights 22.3500 2021-02-27 4 M 0 29838.0000 0.0000 D 2021-02-27 2021-02-27 Common Stock 29838.0000 0.0000 D The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Price is the closing price of Pfizer common stock on February 26, 2021. The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. In connection with the completed spinoff and combination of the Upjohn business with Mylan to create Viatris, and in accordance with their terms, adjustments were made to stock units, by providing additional Pfizer total shareholder return units (Stock Appreciation Rights) to plan participants in lieu of the Viatris dividend provided to shareholders, in order to maintain the same value post-transaction as the value of the outstanding awards prior to the transaction (subject to rounding). Susan E. Grant, by power of atty., for Alexander R. MacKenzie 2021-03-02